StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
9QX.SI$0.01+0.00%
Fair $0.01+0.0%

9QX.SI

Beverly Wilshire Ltd.

Healthcare / Medical Care FacilitiesSES

$0.01

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $0.01Fund rank 20/100 · Data gapFallback financials|
SA 22/D
F-Score: 3/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 14%

FCF escenarios

weak_data · normalized FCF $353000.00 · quality 25.7/100

Data gap 20/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 12/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

22/100

D

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is 4.5%, below the 5% threshold
Thesis & Journal · 9QX.SILocal privado en este navegador · Beverly Wilshire Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$11M

P/E

N/A

•

EV/EBITDA

15.2x

↑

ROE

4.5%

↑

Gross Margin

56.1%

↑

Debt/Equity

1.40

↑
52-Week Range$0
$0$0

TradingView lightweight chart

9QX.SI price, volumen y niveles de valoración

Último $0.009Periodo -99.7%
Fair value: $0.009

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-3.6%

FCF CAGR

—

FCF margin

-12.6%

FCF / Net income

-25.65x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $9.4M · net income $46000.0 · FCF $-1.2M

2022-FY → 2025-FY

Gross margin

56.1%+1.5% pts

Operating margin

-3.1%+18.9% pts

Net margin

0.5%+20.6% pts

FCF margin

-12.6%-4.6% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$9.4M$9.4M$5.9M$8.0M$10.5M
Net Income$46000.00$46000.00$-4.9M$-2.2M$-2.1M
EBITDA$740000.00$740000.00$-4.5M$-886000.00$-266000.00
EPS——-0.01-0.00-0.01
Gross Margin56.1%56.1%52.1%54.7%54.6%
Operating Margin-3.1%-3.1%-49.9%-30.2%-22.0%
Net Margin0.5%0.5%-83.6%-27.6%-20.1%
Balance Sheet
Debt/Equity1.401.40-0.4221.79-3.33
Current Ratio1.011.01———
Cash Flow
Free Cash Flow$-1.2M$-1.2M$1.6M$353000.00$-833000.00
Returns
ROE4.5%4.5%110.2%-1667.7%159.4%
Valuation
EV/EBITDA15.1715.17———
P/B10.1210.12—168.95—
Growth & Yield
Revenue Growth59.7%59.7%-26.8%-23.5%—
EPS Growth——-63.3%9.3%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -35.7%

Total return

-35.7%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.01 → n/d

Residual

-35.7%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-35.7%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.